Mouse version of 3q29 deletion: insights into schizophrenia/ASD pathways

Emory researchers see investigating 3q29 deletion as a way of unraveling schizophrenia’s biological and genetic Read more

B cells off the rails early in lupus

Emory scientists could discern that in people with SLE, signals driving expansion and activation are present at an earlier stage of B cell differentiation than previously Read more

Head to head narcolepsy/hypersomnia study

At the sleep research meeting in San Antonio this year, there were signs of an impending pharmaceutical arms race in the realm of narcolepsy. The big fish in a small pond, Jazz Pharmaceuticals, was preparing to market its recently FDA-approved medication: Sunosi/solriamfetol. Startup Harmony Biosciences was close behind with pitolisant, already approved in Europe. On the horizon are experimental drugs designed to more precisely target the neuropeptide deficiency in people with classic narcolepsy type 1 Read more

Bayh-Dole Act

The Bayh-Dole Act: 30 Years of Innovation

At Emory’s recent Fourth Celebration of Technology and Innovation, faculty researchers and entrepreneurs were recognized for outstanding accomplishments in developing promising technologies that are moving from the laboratory to the marketplace.

Keynote speaker for the annual event was Joseph Allen, a key staff member in helping Senator Birch Bayh (D-IN) secure passage of the Bayh-Dole Act 30 years ago, opening up collaborations between research universities and U.S. industry.

Todd Sherer, executive director of Emory’s Technology Transfer Office, described Emory’s robust product pipeline, which includes products at all stages of development and regulatory approval. The pipeline helps ensure multiple missions of driving academic discoveries, advancing commercially protected technologies, and providing substantial public benefit.

Read more

Posted on by Holly Korschun in Uncategorized Leave a comment